ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule Inhibitor of C5aR, at the 49th European …

MOUNTAIN VIEW, Calif. -- ChemoCentryx, Inc. , today announced the presentation of results from the Company's development program for CCX168, an investigational orally administered inhibitor of the complement ...